CoChat

Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial

Open access

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Abstract

Background Continuous glucose monitoring, either real-time (personal) or retrospective (professional mode), can identify day-to-day glucose profiles to guide management decisions for people with type 2 diabetes. We aimed to examine the effects of professional-mode flash glucose monitoring, done at 3-month intervals, in adults with type 2 diabetes in general practice. Methods We did a pragmatic, two-arm, open label, 12-month, individually randomised controlled trial (GP-OSMOTIC) in 25 general practices in Victoria, Australia. Eligible participants were adults aged 18-80 years, with type 2 diabetes diagnosed for at least 1 year and HbA 1c at least 5·5 mmol/mol (0·5%) above their target in the past month despite being prescribed at least two non-insulin glucose-lowering drugs, insulin, or both (with therapy stable for at least 4 months). We randomly assigned participants (1:1) to either use of a professional-mode flash glucose monitoring system or usual clinical care (control). All participants wore the flash glucose monitoring sensor at baseline, and electronic randomisation (using permuted block sizes of four and six, and stratified by clinic) was done after the sensor was attached. Masking of participants and treating clinicians to group allocation was not possible, but the study statistician was masked to allocation when analysing the data. At baseline, and 3, 6, 9, and 12 months, participants in the flash glucose monitoring group wore the professional-mode flash glucose mon…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(19)30385-7

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. Young, 2015, Examining the role of continuous glucose monitoring (CGM) in noninsulin treated type 2 diabetes, Diabetes, 64, A236

Cited by

See all 65

Metadata

Authors
Furler, J., O'Neal, D., Speight, J., Blackberry, I., Manski-Nankervis, J.-A., Thuraisingam, S., de La Rue, K., Ginnivan, L., Doyle, R., Holmes-Truscott, E., Khunti, K., Dalziel, K., Chiang, J., Audehm, R., Kennedy, M., Clark, M., Jenkins, A., Lake, A. J., Januszewski, A. S., Catchpool, M., Liew, D., Clarke, P., & Best, J.
Affiliations
  • The University of Melbourne (AU)
  • Deakin University (AU)
  • La Trobe University (AU)
  • University of Leicester (GB)
  • The University of Sydney (AU)
  • Monash University (AU)
  • Nanyang Technological University (SG)
Corresponding author
Furler, John
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2020-01
Volume
8
Issue
1
Pages
17-26
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2995952001
Cited by
55
References
28
Citations by year
2026: 6 · 2025: 9 · 2024: 5 · 2023: 10 · 2022: 7 · 2021: 12 · 2020: 5
FWCI
5.07
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Health and Medical Research Council (APP1104241)
  • Deakin University
  • Novo Nordisk
  • Roche
  • AstraZeneca Australia
  • Sanofi Australia
  • National Institute for Health and Care Research
  • Center for Outcomes Research and Evaluation, Yale School of Medicine
  • National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care Yorkshire and Humber
  • Boehringer Ingelheim
  • NIHR Leicester Biomedical Research Centre
  • Abbott Diabetes Care
  • Diabetes Victoria
  • Manchester Biomedical Research Centre
  • Sydney Medical School Foundation
  • Medtronic
  • Collaboration for Leadership in Applied Health Research and Care - Greater Manchester
  • Sanofi
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
flash glucose monitoring, type 2 diabetes, HbA1c, glycemic control, ambulatory glucose profile, time in target glucose range, diabetes distress, general practitioner care, primary care, diabetes management, HbA1c targets, Problem Areas in Diabetes scale, HbA1c variability, HbA1c trends
MeSH terms
Aged, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Monitoring, Physiologic, Blood Glucose Self-Monitoring, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30385-7
The paper
Furler, J., O'Neal, D., Speight, J., Blackberry, I., Manski-Nankervis, J.-A., Thuraisingam, S., de La Rue, K., Ginnivan, L., Doyle, R., Holmes-Truscott, E., Khunti, K., Dalziel, K., Chiang, J., Audehm, R., Kennedy, M., Clark, M., Jenkins, A., Lake, A. J., Januszewski, A. S., . . . Best, J. (2020). Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30385-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.